Enterprise Value
455.7M
Cash
329.4M
Avg Qtr Burn
-33.86M
Short % of Float
10.34%
Insider Ownership
0.00%
Institutional Own.
-
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Bezuclastinib (CGT9486) (KIT exon 17 inhibitor) + Sunitinib Details Cancer, Gastrointestinal stromal tumors | Phase 3 Update | |
Bezuclastinib (CGT9486) (KIT exon 17 inhibitor) Details Systemic Mastocytosis Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 2 Data readout | |
Bezuclastinib (CGT9486) (KIT exon 17 inhibitor) Details Systemic Mastocytosis Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 2 Data readout |